AstraZeneca Etcamah trial fails primary endpoint
AstraZeneca said its Etcamah plus palbociclib study in ER-positive, HER2-negative advanced breast cancer did not meet its primary endpoint.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.